These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24400127)

  • 1. Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.
    Sripetchwandee J; Pipatpiboon N; Chattipakorn N; Chattipakorn S
    PLoS One; 2014; 9(1):e85115. PubMed ID: 24400127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
    Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
    Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.
    Kumfu S; Khamseekaew J; Palee S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Free Radic Res; 2018 Jan; 52(1):70-79. PubMed ID: 29207893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
    Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
    Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload.
    Sripetchwandee J; Sanit J; Chattipakorn N; Chattipakorn SC
    Life Sci; 2013 Mar; 92(4-5):298-304. PubMed ID: 23333832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment.
    Alcalde LA; de Freitas BS; Machado GDB; de Freitas Crivelaro PC; Dornelles VC; Gus H; Monteiro RT; Kist LW; Bogo MR; Schröder N
    Biometals; 2018 Dec; 31(6):927-940. PubMed ID: 30117045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice.
    Sangartit W; Pakdeechote P; Kukongviriyapan V; Donpunha W; Shibahara S; Kukongviriyapan U
    Vascul Pharmacol; 2016 Dec; 87():199-208. PubMed ID: 27713040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferiprone and efonidipine mitigated iron-overload induced neurotoxicity in wild-type and thalassemic mice.
    Sripetchwandee J; Khamseekaew J; Svasti S; Srichairatanakool S; Fucharoen S; Chattipakorn N; Chattipakorn SC
    Life Sci; 2019 Dec; 239():116878. PubMed ID: 31669736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.
    Kumfu S; Khamseekaew J; Palee S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Eur J Pharmacol; 2018 Mar; 822():43-50. PubMed ID: 29366843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study.
    Sriwichaiin S; Thiennimitr P; Thonusin C; Sarichai P; Buddhasiri S; Kumfu S; Nawara W; Kittichotirat W; Fucharoen S; Chattipakorn N; Chattipakorn SC
    Life Sci; 2022 Oct; 307():120871. PubMed ID: 35952729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.
    Agrawal S; Fox J; Thyagarajan B; Fox JH
    Free Radic Biol Med; 2018 May; 120():317-329. PubMed ID: 29625173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).
    Berdoukas V; Bohane T; Eagle C; Lindeman R; DeSilva K; Tobias V; Painter D; Fraser I
    Transfus Sci; 2000 Dec; 23(3):239-40. PubMed ID: 11099900
    [No Abstract]   [Full Text] [Related]  

  • 16. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron and oxidative stress in cardiomyopathy in thalassemia.
    Berdoukas V; Coates TD; Cabantchik ZI
    Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
    Alta EC; Goswami D; Machini MT; Silvestre DM; Nomura CS; Espósito BP
    Biometals; 2014 Dec; 27(6):1351-60. PubMed ID: 25265871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.